TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of dementia of the Alzheimer type (DSM-IV Text Revision (TR) criteria)~2. Mini-mental state examination (MMSE) \>18, but \<29~3. Apathy Evaluation Scale (AES) score of more than 40~4. Ability to provide informed consent by either the patient or caregiver.~5. If subjects are being treated with antidepressants, they should be on a stable dose of antidepressants for at least two months prior to the enrollment into the study.~6. If subjects are being treated with cholinesterase inhibitors and memantine, they should be on stable dose of those medications at least four months prior to the enrollment into the study.~Exclusion Criteria:~1. Patient currently taking methylphenidate or hypersensitivity or prior significant adverse events with methylphenidate.~2. Patients currently taking Adderall (amphetamine mixed salts) or Dexedrine (dextroamphetamine sulphate) or any other amphetamine product.~3. Uncontrolled hypertension (BP \> 140/90) or tachycardia (100) at screening visit~4. Patients with frontotemporal dementia~5. Patients meeting criteria for Major Depressive Disorder on the Mini International Neuropsychiatric Inventory (MINI)~6. Patients with active psychosis as determined by MINI~7. Patients currently being treated with antipsychotics~8. History of uncontrolled seizure disorder~9. History of malignant hypertension, symptomatic cardiovascular disease, cardiomyopathy, known structural cardiac defect or medically unstable arrhythmias.~10. History of Tourette's syndrome or presence of motor tics~11. Patients with glaucoma~12. Patients taking monoamine oxidase inhibitors (MAOIs)~13. Patient taking clonidine

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Methylphenidate
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 6 years of age~* Diagnosis of asthma~* Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol~Exclusion Criteria:~* Severe asthma~* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers~* Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort
- 2 (Type: ACTIVE_COMPARATOR): budesonide
- 3 (Type: ACTIVE_COMPARATOR): formoterol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>=18 to \<=55 years of age~* Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6 months prior to Screening~* Willing to refrain from using carbohydrate counting to adjust insulin during the study~* Willing and able to wear and operate a continuous glucose monitor~* Willing and able to self-assess blood glucose~* Willing and able to provide written informed consent.~Exclusion Criteria:~* History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's disease, chronic pancreatitis, or pancreatectomy~* Two or more severe episodes of hypoglycemia that required emergency treatment within 3 months prior to Screening~* Use of premixed insulin~* History of diabetic ketoacidosis within 1 year of screening~* Presence of active hepatic disease or clinically significant abnormal liver function tests~* History of chronic pancreatitis~* Participants with a history of heart attack, severe/unstable angina, or coronary revascularization procedure~* History of clinically significant cardiac arrhythmias within 1 year prior to screening~* Participants with congestive heart failure~* Participants with uncontrolled Stage III hypertension~* History of human immunodeficiency virus (HIV) or hepatitis C~* History of illicit drug or alcohol abuse within 12 months prior to Screening~* Use of any investigational agent or device within 30 days prior to Screening or any therapeutic protein or antibody within 90 days prior to Screening~* Use of medication or herbal supplements taken for weight loss within 2 weeks of screening~* Chronic use of any antidiabetic therapy other than insulin within 2 months prior to Screening~* Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening~* Participants who underwent major surgery within 6 months prior to Screening~* Inability or difficulty swallowing whole tablets or capsules~* Women who were pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Sotagliflozin 400 mg - Pioneer Group (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
- Placebo - Expansion Group (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
- Sotagliflozin 400 mg - Expansion Group (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bacterial skin and skin structure infection with a complicating factor, (including a pre-existing skin lesion, or a condition affecting the way the drug gets to the infected area of the body, the body's disease defense (immune) system, or the ability of tissues to heal properly)~* have at least 2 of the following signs and symptoms of skin infection: pain, redness, swelling, hardness, pus formation~* have an infection of one of the following types: wound infections (crush, puncture, cut, gunshot, surgery, bite), infected skin ulcers, or infections in patients with decreased immune system function (HIV infections, diabetes, etc)~* able to provide a sample of tissue from the affected area of the skin~Exclusion Criteria:~* Patients with multiple infected ulcers at separate locations on body~* requiring immediate surgery at the infection site~* having low blood pressure, decreased urination, decreased kidney function, seizure disorder, unstable mental disorder, low white blood cell count, bone infection, shock, or are HIV positive~* having an infection from a bacteria known to be resistant to any of the study drugs~* having a previous allergic or serious reaction to any of the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Movement-Oriented Behavioral Activation (MOBA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pilot cohort will be composed of food service workers drawn employee by sponsor's organization. The age range was chosen to target the critical window for establishing the long-term geroprotective benefits of increasing movement-oriented behaviors. The workplace cohort was chosen because their work demands are characterized by a high level of stationary activity.~Exclusion Criteria:~1) individuals with moderate or greater depression severity (PHQ-9 \> 14); and 2) individuals with significant mobility limitation, defined as inability to complete 6 Minute-Walk Test.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Randomly selected to participate first in MOBA group
- Wait-list-control group (Type: OTHER): Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* CIU diagnosis \> 3 months (by history)~* No underlying etiology clearly defined for urticaria (main manifestation cannot be physical urticaria)~Exclusion Criteria:~* Pregnant, breastfeeding, or women not taking contraception~* Patients \< 40kg~* Treatment with any investigational agent within 30 days of screening~* Recent history of drug or alcohol abuse~* Atopic dermatitis or other skin disease associated with pruritus~* Clinically relevant major systemic disease (making interpretation of the study results difficult)~* Previously treated with omalizumab (\< 12 months since last injection)~* Patients may not take during treatment period or have been taking within the past 3 months any of the following medications/treatments: regular (daily/every other day) hydroxychloroquine, methotrexate, cyclosporine, cyclophosphamide, IVIG, or plasmapheresis~* Patients may not have been taking doxepin within the past 6 weeks regular (daily/every other day).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab 75 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
- Omalizumab 300 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
- Omalizumab 600 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Documented history of migraine in the 12 months prior to screen~2. at least 4 days per month of migraine symptoms~3. \>=80% diary compliance during the Baseline period~4. Patients must be either naïve or not suitable or have failed previous migraine prophylactic treatments~Key Exclusion Criteria:~1. Older than 50 years of age at migraine onset~2. Pregnant or nursing~3. History of cluster or hemiplegic headache~4. History or evidence of major psychiatric disorder~5. Score of 19 or higher on Beck Depression Inventory (BDI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): 70 mg and 140 mg Erenumab
- Topiramate (Type: ACTIVE_COMPARATOR): Topiramate in the highest tolerated dose (50 - 100 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed locally advanced/metastatic (stage IIIB/stage IV, using the American Joint Committee on Cancer \[AJCC\] 6th edition of tumor-node-metastasis \[TNM\] staging system) NSCLC patients~* Progressed after at least one platinum-based chemotherapy regimen at entry~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.0~* Adequate hematologic and biochemical values~Exclusion Criteria:~* Patients with symptomatic brain metastases~* Malignant tumor within the previous five years~* Severe infection; congestive heart failure~* Previous treatment with drugs targeting EGFR~* History of interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- icotinib (Type: EXPERIMENTAL): Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18, either sex~* Histologically confirmed stage IV nasopharyngeal cancer~* One bone metastasis at least confirmed by imaging~* without chemotherapy or radiotherapy after bone metastasis~* Life expectancy \> 6 M~* ECOG \<= 2~* Adequate bone marrow reserve (WBC \> 3.5 x 109/L, Neutrophile \> 1.5 x 109/L, Platelet 100 x 109/L, Hb \> 90 g/L)~* Serum creatinine\< 2.0 mg/dL (\< 1.5 times the upper limit of the normal range for the laboratory of the study center)~* Signed ICF~Exclusion Criteria:~* Women who are pregnant or in lactation~* Patients with hyperostosis~* Systemic treatment for another cancer within the year prior to study entry~* Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy~* Initial serum creatinine \>265 micromol/L and/or progressive renal disease~* Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures~* Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies~* Severe co-morbidity of any type that may interfere with assessment of the patient for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
- Contorl Group (Type: NO_INTERVENTION): Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stellate Ganglion Nerve Block in Treating Women With Hot Flashes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Presence of hot flashes for ≥ 1 month prior to study registration~  * Hot flashes considered bothersome (defined by their occurrence of ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)~* Use of more conventional hot flash treatments (including newer antidepressants and gabapentin) have failed to control hot flashes (as defined by the patient)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 6 months~* Not of childbearing potential, as judged by the attending clinician~* Able to complete questionnaires alone or with assistance~* No evidence of an active malignancy~* No von Willebrand's disease or other bleeding disorders~* No allergy to chlorhexidine or bupivacaine~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents~  * Tamoxifen, raloxifene, or aromatase inhibitors allowed provided the patient has been on a constant dose for ≥ 4 weeks and continues to receive medication during study treatment~* More than 10 days since prior and no concurrent anticoagulants (e.g., aspirin, clopidogrel, ticlopidine, or warfarin)~  * Concurrent heparin flushes for venous catheter allowed~* No concurrent use of other agents (e.g., megestrol acetate, soy, clonidine, or Bellergal) for treating hot flashes~  * Vitamin E, gabapentin, or antidepressants allowed provided the patient has been on a stable dose for \> 30 days and continues to receive medication during study treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients being attended by the mobile stroke unit with an acute ischemic stroke eligible for thrombolysis using standard clinical and CT criteria.~2. Patient's age is ≥18 years~3. Premorbid mRS \<4~Exclusion Criteria:~1. Intracranial hemorrhage (ICH) or other diagnosis (e.g. tumor) identified by CT on the MSU~2. Hypodensity in \>1/3 MCA territory or equivalent proportion of ACA or PCA territory on non-contrast CT on MSU~3. Pre-stroke mRS score of \> 3 (indicating significant previous disability)~4. Any terminal illness such that patient would not be expected to survive more than 1 year~5. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.~6. Pregnant women.~7. Rapidly improving symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous tenecteplase (TNK) (Type: ACTIVE_COMPARATOR): Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).
- Intravenous tissue plasminogen activator (tPA) (Type: ACTIVE_COMPARATOR): Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete